On January 8, 2021, we bought an additional 8 shares of Viatris (NASDAQ: VTRS) paying $18.39 per share for our Partnership Fund. Viatris is the latest addition to our Partnership fund.
VTRS is a spinoff from Pfizer stock (which we hold already 100 shares), and it was decided to keep investing in this stock until we will reach 100 shares and will be able to sell covered calls on it.
We are now holding 70 shares of VTRS in our Partnership Fund portfolio
Using dollar-cost averaging our average cost per one VTRS share is $15.91
30 shares to go once we will be able to start selling covered calls and generate extra income from VTRS. We are looking to get there in February 2021
If we had 100 shares of VTRS today, we could sell February 19, 2021, covered call (monthly options) with a strike price of $19, to get a $0.20 premium. In case our shares would get called away on expiry we would realize $329 income in 32 days.
By now VTRS takes 3.66% from our US stock portfolio.
Viatris is a global pharmaceutical company that believes in healthcare not as it is, but as it should be